A Randomized, Double-blind, Placebo-controlled, Parallel-group, Phase 3 Study of ITM-058 in Patients with Osteoporosis
Latest Information Update: 24 Aug 2022
Price :
$35 *
At a glance
- Drugs Abaloparatide (Primary)
- Indications Osteoporosis
- Focus Registrational; Therapeutic Use
- Acronyms ACTIVE-J
- Sponsors Teijin Pharma
- 17 Aug 2022 Results published in the Journal of Clinical Endocrinology and Metabolism
- 09 Sep 2020 According to a Radius Health media release, Teijin Pharma Limited will be sharing detailed data from this study at the upcoming American Society for Bone and Mineral Research (ASBMR) 2020 Annual Virtual Meeting.
- 27 May 2020 Primary endpoint (Increase in lumbar spine bone mineral density at 18 months) has been met, according to a Radius Health media release.